MRC

MRC – Deadline: 14 Mar 2018

Biomedical Catalyst: Regenerative Medicine Research Committee

Supports translation of fundamental discoveries toward benefits to human health.

The translation of the burgeoning knowledge in regenerative medicine into new treatment strategies is a key objective of the MRC’s strategic plan. The Biomedical Catalyst: Regenerative Medicine Research Committee (RMRC) provides support for high quality proposals that may underpin or progress the development of  regenerative medicine therapies to improve human health. The RMRC:

  • Supports confidence in concept studies that if successful will promote the translation of fundamental discoveries toward benefits to human health, thereby accelerating the transition from discovery research to mature translational development projects
  • Funds preliminary work or feasibility studies to establish the viability of an approach, through addressing focussed research questions needed to unlock progress in pre-clinical development and/or early clinical testing of novel regenerative medicine therapies
  • Forms part of the MRC’s Translational Research Strategy and forms part of the Biomedical Catalyst funding stream, operating in conjunction with the Developmental Pathway Funding Scheme

For more information please visit the MRC website.

Advertisements

MRC – Deadline: 28 Mar 2018

Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)

The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

Remit

The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.

Projects supported by the scheme have up to four clearly defined milestones, outcomes and future plans. These help to maximise both the chance of success and the likelihood of the project attracting the downstream funding, from public or private sources, required to meet its clinical and commercial aims. The funding panels assessing the project will, if necessary, help to develop proposals and suggest enhancements.

The following activities are eligible for support:

  • Developing candidate therapeutic entities (e.g. drug discovery)
  • Pre-clinical testing of novel therapeutic entities
  • Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
  • “Repurposing” clinical studies – using existing therapies for new indications
  • Developing and testing novel devices
  • Developing and testing diagnostics (including biomarker validation)

Individual projects can start and finish at any point along the translational pathway but would not typically progress from initial development through to phase 2 clinical testing in a single application. Where there is a justified need for continued MRC support, sequential applications are encouraged.

All disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, cell and gene therapy, devices, surgical techniques and psychological approaches.

 

For more information please visit the MRC website.

MRC – Deadline: 5 Apr 2018

Clinical Research Training Fellowship (CRTF) – pre-doctoral

The CRTF supports clinicians, including (but not limited to) medics, surgeons, dentists, clinical psychologists, public health specialty trainees, allied health professionals, nurses, midwives and veterinarians, to undertake a PhD or other higher research degree.

Clinical Research Training Fellowship (CRTF) – post-doctoral

The scheme also provides a route for post-doctoral applicants who achieved their PhD some time ago but who have not been research active since due to clinical training commitments to reacquire research skills.

For more information please visit the MRC website.

MRC – Deadline: 5 Apr 2018

Senior Clinical Fellowship (SCF)

Purpose of scheme

The SCF supports talented medically and other clinically qualified professionals, with an effective  track record of internationally competitive independent research, to make the transition to research leadership.

A SCF provides funding for a challenging research programme, and an ambitious programme of research training which offers accelerated personal and career development.

Applicants wishing to retain an existing position and combine this with research funding, should consider funding options under one of the grant schemes.

For more information visit the MRC website.

MRC – Deadline: 25 Apr 2018

Senior Non-Clinical Fellowship

Purpose of scheme

The SNCF supports researchers with a track record of effectively leading their own independent research to make the transition to research leadership and become an internationally recognised leader in their field.

An SNCF provides funding for a challenging research programme, and an ambitious programme of research training which offers accelerated personal and career development.

Applicants wanting to retain an existing position and combine this with research funding, should consider funding options under one of the grant schemes.

For more information please visit the MRC website.

MRC – Deadline: 25 Apr 2018

Career Development Award (CDA)

Purpose of scheme

The CDA supports talented post-doctoral researchers to lead their own research plans and establish their own research team to make the transition from post-doctoral researcher to independent investigator.

A CDA provides funding for a challenging research programme, and an ambitious programme of research training which offers accelerated personal and career development.

Applicants wishing to retain an existing position and combine this with research funding, should consider funding options under one of the grant schemes. You may wish to pay particular attention to the New Investigator Research Grant scheme, which aims to support individuals wanting to transition to independence.

For more information please visit the MRC website.

MRC – Deadline: 2 May 2018

New Investigator Research Grant – Molecular & Cellular Medicine 

The New Investigator Research Grant (NIRG) is aimed at researchers who are capable of becoming independent Principal Investigators and who are now ready to take the next step towards that goal. You can apply across all areas of the MRC’s remit.

For more information please visit the MRC website.

MRC – Deadline: 2 May 2018

Programme grants – Molecular & Cellular Medicine – Research Boards:

Programme grants provide larger, longer term (five years) and renewable programme funding. They aim to help the medical science community to ‘think bigger’. A programme is defined as a coordinated and coherent group of related projects, which may be developed to address an inter-related set of questions across a broad scientific area.

For more information please visit the  MRC website.

 

MRC – Deadline: 16 May 2018

Programme grants – Infections and Immunity (IIB) – Research Boards:

Programme grants provide larger, longer term (five years) and renewable programme funding. They aim to help the medical science community to ‘think bigger’. A programme is defined as a coordinated and coherent group of related projects, which may be developed to address an inter-related set of questions across a broad scientific area. 

For more information please visit the MRC website.